Stem Cell–Based Therapies for Sepsis
Beyza Nur Akı1, İrem Adar1, Yaren Feryal Erenay1, Oytun Erbaş1
1ERBAS Institute of Experimental Medicine, Illinois, USA & Gebze, Türkiye
Keywords: Acute respiratory distress syndrome, cytokine storm, immunotherapy, SARS-CoV-2, sepsis, stem cell.
Abstract
Sepsis, a life-threatening condition triggered by the body's response to infection, presents significant healthcare challenges. This examines the potential of mesenchymal stem cells (MSCs) as a promising therapeutic strategy for sepsis, particularly for coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and neurological disorders. Preliminary clinical studies have demonstrated the safety and efficacy of MSC therapy for both COVID-19 patients and sepsis cases. However, inconsistencies in inclusion and exclusion criteria across studies highlight the need for further multicenter, randomized, controlled trials and long-term follow-up to identify the ideal patient population for MSC therapy. Mesenchymal stem cells possess anti-inflammatory and immune-modulatory properties, making them a justifiable treatment option for COVID-19-induced ARDS. Additionally, discusses the potential of MSCs to enhance bacterial clearance, reduce inflammation, and improve survival rates in sepsis. Furthermore, it explores the application of stem cell-based therapies in addressing neurological disorders associated with sepsis. The integration of combination therapies, including MSCs, holds promise for the treatment of sepsis and its associated complications. This chapter gives general information about the importance of ongoing research to address challenges such as cell tumorigenesis and the customization of MSC-based therapies for optimal clinical outcomes. Furthermore, it highlights the significant potential of MSC therapy in improving treatment outcomes for sepsis, COVID-19, ARDS, and neurological disorders. The utilization of MSCs in these conditions has shown promising results, including enhanced bacterial clearance, reduced inflammation, and increased patient survival rates. Through continuous research efforts, we aim to further understand and maximize the therapeutic benefits of MSC-based treatments in various medical contexts.
Cite this article as: Akı BN, Adar İ, Erenay YF, Erbaş O. Stem Cell–Based Therapies for Sepsis. JEB Med Sci 2024;5(1):101-111.
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
The authors received no financial support for the research and/or authorship of this article.